Form D · Biotechnology

Breethe, Inc.

Halethorpe, MD · CIK 0001631734

Offering snapshot reported Jul 12, 2019 · SEC filing

Reported sold
$8M
Offering amount: $8M
Investors reported
24
Form D · investor count
Minimum accepted
$1
Reported outside-investor minimum
First sale
Jun 7, 2019
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$4M$8MJun 20, 2019: $6,000,000.00Jun 20, 2019Jul 12, 2019: $8,000,000.00Jul 12, 2019

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$6,000,000 → $8,000,000
  • Reported investors23 → 24

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 12, 2019Amendment$8,000,000$2,000,000vs Jun 20, 201924SEC filing
Jun 20, 2019Initial$6,000,000No comparison23SEC filing
Oct 1, 2018Initial$3,512,513No comparison29SEC filing
Dec 21, 2017Initial$2,999,999No comparison22SEC filing
Aug 25, 2017Initial$1,149,993No comparison7SEC filing
Aug 17, 2016Initial$2,175,000No comparison20SEC filing
Sep 8, 2015Initial$575,000No comparison6SEC filing
Jan 26, 2015Initial$810,000No comparison5SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$120K
Finders' fees
$0
Form D file number
021-342366
This filing covers the sale and issuance of Series 6 Preferred Stock and the underlying Common Stock issuable upon conversion thereof.
In addition to the sales commission of $120,000, Recipient received from Issuer a warrant that is exercisable into 16,000 shares of Common Stock at the exercise price equal to the Series 6 per-share price.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Gravitas Healthcare Partners, LLCNoneINTE SECURITIES LLC · CRD 47107

Source: Form D, filed Jul 12, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Michael Cippel Executive
Carl A. Cohen Director
Donald W. Fallon Executive
Bartley Griffith Director
Marshal Linder Director, Executive
Steven Orwig Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1500 Joh Avenue Suite 190
Halethorpe, MD, 21227